both being developed for the treatment of cancer. Previous research has shown that these pan-KRAS inhibitors target KRAS in the inactive OFF state, while sparing HRAS and NRAS.
A lethal, mutant version of the KRAS signaling enzyme was often called undruggable—until researchers found a molecule that has the potential to lock onto this cancer-causing protein.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback